Member Info for thevid

2&6.... you`re a dodgy barsteward ;)

Another 17298 @ 28.9 for me :). Bargain.

Moderna’s Next Act Is Using mRNA vs. Flu, Zika, HIV, and Cancer
an hour ago.

04 Feb 2019

Moderna Exercises Option for an Exclusive Product License

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. (NASDAQ: MRNA) has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies.

In 2015, Avacta and Moderna entered into a collaboration, license and option agreement under which Moderna was granted exclusive access to Avacta’s Affimer technology for certain collaboration targets and the option to enter into exclusive license agreements on pre-agreed terms to further research, develop and commercialize Affimers selected by Moderna.

Under the terms of the agreement Avacta may receive undisclosed payments upon future clinical development milestones and royalties in connection with future product sales.

Dr Alastair Smith, Avacta Group Chief Executive Officer, commented:
“I am delighted to report that Moderna has exercised its option to enter into this exclusive license agreement with respect to certain Affimer molecules that have been generated through our collaboration. This is further strong validation of the potential of the Affimer drug platform to generate differentiated therapeutic molecules for development.

We will continue to support Moderna and their development objectives and I look forward to updating the market as and when key development milestones are met.”

Wed, 22nd Jun 2016 07:00
RNS Number : 8890B
Avacta Group PLC
22 June 2016


Avacta Rapidly Generates Affimer Binders for Zika Virus Diagnostics





· Rapid generation and validation of three distinct and highly specific Affimer binders to Zika virus within just thirteen weeks of receiving the virus target.

· The Affimer reagents bind a protein called NS1 which is diagnostic of the early, acute stage of Zika infection and for which no validated antibody is available.

· Highlights the potential of Affimer technology to support global rapid response for novel point-of-care diagnostics and health screening.





Wetherby, UK, 22nd June 2016: Avacta Group plc (AIM: AVCT) ("Avacta" or "the Group"), the developer of Affimer® biotherapeutics and research reagents, today announced it has identified three Affimer proteins capable of binding to a recombinant form of a secreted Zika virus NS1 protein (Non-Structural protein 1), which is diagnostic of Zika virus infection at the early, acute stage. These Affimer binders were identified and characterised within just thirteen weeks of receiving the virus target and have the potential to be developed into new rapid point-of-care diagnostic tests for Zika infection.



The three Affimer binders are highly specific to the Zika NS1 protein and can differentiat

19th shorn

Ged Hall, London-based Director of Castillo Copper, remarked: "The BHA Project is an excellent asset as it comprises a substantial prospective footprint surrounding the world-famous Broken Hill silver-zinc-lead mine. The Board has considered the most effective way to deliver value for shareholders and we are confident that our intent to spin this asset out into a new vehicle will be well received and supported by UK investors."

The Board is currently liaising with its UK corporate advisor, SI Capital, on the optimal way to move this proposed corporate action forward in a timely manner

Holding the fort well chesh, :)

Hemos ApbHC –Humanized Mouse Model is and always has been a major advantage to hemo. Apart from the revenue this will provide, it must increase the % chance of success in at least trials 1 & 2 having developed the pipeline using them.

De-risked:Established sound proof-of-principle in humanized animal studies Humanized mice:
Finding wider acceptance in the pharma community and represent an immediate income source for the company

Just the smallest bit of research shows the massive potential of this company.

Just bought in :)

I believe he had a on going groin injury.

Very good presentation, professional and informative . Only patience needed here chaps....... just patience.

No, you should not take any notice of anyone but yourself.

Pretty much as expected, all good and lots of news to come.

Do we believe one post dave

zzzzzzzzzzzzzzz

Think i`ll go for a late afternoon nap.

bout 4.30

Good find baffy

The proof is in the pudding.

All good, gl